Milestone Capital China
VC Fund
Shanghai, China
Milestone Capital China is a VC fund in Shanghai focused on Health Care and Biotechnology. Milestone Capital manages the Milestone China Opportunities Fund I, L.P., the Milestone China Opportunities Fund II, L.P., the Milestone China Opportunities Fund III, L.P. (the “Funds”), as well as the Milestone Kunshan Investment Fund, L.P. (the “RMB Fund”) which invest primarily in established high-growth companies seeking expansion oracquisition capital in China. The Funds seek to maximize medium to long term capital appreciation by making direct investments to acquire minority or majority equity stakes in those companies identified by Milestone’s investment team. The Funds’ investment size typically ranges between US$ 10 million to US$ 100 million. The RMB Fund’s investment size ranges between RMB 20 million to RMB 80 million. The Funds invest in a limited number of portfolio companies where the Milestone Capital team can dedicate significant resources to each portfolio company.Milestone Capital’s success formula is predicated on proprietary deal flows, professional due diligence, disciplined investment approach, creative structuring and proactive monitoring with a focus on value creation. Milestone Capital usually requires board representation and stringent shareholder protection commensurate with its shareholding.Milestone Capital has a strong track record in helping portfolio companies list on either domestic or foreign stock exchanges. We leverage our extensive network of advisors, industry executives, portfolio companies as well as business relationships to bring superior value-added support to our portfolio companies from both financial and strategic angles.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Milestone Capital China invests in
Stages Milestone Capital China invests in
Countries Milestone Capital China invests in
Investment Focus
Industry
- Health Care 3 (60%)
- Biotechnology 3 (60%)
- Medical 2 (40%)
- Manufacturing 2 (40%)
- Pharmaceutical 2 (40%)
Stage
- Series A 2 (40%)
- Series C 2 (40%)
- Series D 1 (20%)
Country
- China 3 (60%)
- Taiwan 1 (20%)
- Singapore 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Breton
|
Breton develops and manufactures electric heavy-duty truck intelligent solutions with technology for the scened transportation capacity. The company's independent research and development includes core components such as powertrain, battery PACK and temperature management system. It has the technology-leading R&D and design integrationcapability of pure electric heavy trucks, which greatly reduces the industrial chain cost of pure electric heavy trucks. Proactively define new energy smart heavy trucks and build a scened logistics capacity service model. Work closely with traditional OEMs to promote integration and innovation, and promote industrial cooperation and win-win. A seamless connection between driverless, pure electric heavy trucks and logistics scenes.The company was founded in 2016 and officially opened in March 2018. | Series C / Jul 20, 2022 | |
No-Antibiotics
|
No-Antibiotics is a phage drug developer specializing in the development of phage and veterinary drug products in the field of animal protection. The company focuses on bacteria with high incidence and serious drug resistance in animal husbandry, including staphylococcus and salmonella. Pseudomonas aeruginosa, respiratory actinomycetes, bacterialdiseases of aquatic animals, etc. Nuoan Baite has been invested and established by entrepreneurs and professors who have served China's insurance industry for many years. It is committed to the development of antibiotic alternative medicine phage products, providing solutions for bacterial diseases for the healthy development of China's planting and breeding industries. The company has a high-level research and development team, perfect R & D and production facilities, has become a leading company in the industrialization of phage technology. | $2.8M / Series A / May 22, 2019 | |
Jiuxin Medical
|
Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the productsdeveloped have complete independent intellectual property rights. | $3M / Series A / Jan 18, 2019 | |
ASLAN Pharmaceuticals
|
ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets. | $23M / Series D / Jul 04, 2016 | |
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $45.6M / Series C / May 11, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Milestone Capital China invest in?
Milestone Capital China invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Milestone Capital China last invest?
The most recent investment recorded for Milestone Capital China closed in Jul 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
